Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Nature | Jul 26, 2012

Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

Pubmed ID: 22763448 RIS Download

Mesh terms: Antineoplastic Agents | Breast Neoplasms | Cell Line, Tumor | Cell Survival | Drug Resistance, Neoplasm | Female | Hepatocyte Growth Factor | Humans | Indoles | Ligands | Melanoma | Mitogen-Activated Protein Kinases | Phosphatidylinositol 3-Kinases | Protein Kinase Inhibitors | Proto-Oncogene Proteins B-raf | Quinazolines | Receptor Protein-Tyrosine Kinases | Receptor, ErbB-2 | Signal Transduction | Sulfonamides

Antibody Registry (Reagent, Antibodies)

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb antibody

Phospho-HER3/ErbB3 (Tyr1289) (21D3) Rabbit mAb mouse, canine, rat, human, h, (m, r, dg)

antibody

View all literature mentions

EGFR (phospho Y1068) antibody

EGFR (phospho Y1068) antibody human, rat, human, rat

antibody

View all literature mentions

Phospho-ALK (Tyr1604) Antibody

Phospho-ALK (Tyr1604) h, human

antibody

View all literature mentions

Phospho-Met (Tyr1234/1235) Antibody

Phospho-Met (Tyr1234/1235) human, mouse, rat, non-human primate, h, m, r, mk

antibody

View all literature mentions

Phospho-HER2/ErbB2 (Tyr1248) Antibody

Her2 / ErbB2, phospho (Tyr1248) human, mouse, rat

antibody

View all literature mentions

Anti-PARP Purified 50 uL antibody

PARP (Poly-ADP-Ribose-Polymerase-1) human, mouse, rat

antibody

View all literature mentions

Bek (C-17) antibody

Bek (C-17) mouse, rat, human, mouse, human, rat

antibody

View all literature mentions

Flg (H-76) antibody

Flg (H-76) human, mouse, rat, mouse, rat, human

antibody

View all literature mentions